Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial
Halme, A. L. E.; Laakkonen, S.; Rutanen, J.; Nevalainen, O. P. O.; Sinisalo, M.; Horstia, S.; Mustonen, J. M. J.; Pourjamal, N.; Vanhanen, A.; Solidarity Finland Investigators, ; Rosberg, T.; Renner, A.; Perola, M.; Paukkeri, E.-L.; Patovirta, R.-L.; Parkkila, S.; Paajanen, J.; Nykanen, T.; Mantyla, J.; Myllarniemi, M.; Mattila, T.; Leinonen, M.; Kulmasu, A.; Kuutti, P.; Kuitunen, I.; Kreivi, H.-R.; Kilpelainen, T. P.; Kauma, H.; Kalliala, I. E. J.; Jarvinen, P.; Hankkio, R.; Hammaren, T.; Feuth, T.; Ansakorpi, H.; Ala-Karvia, R.; Guyatt, G. H.; Tikkinen, K. A. O.
Show abstract
We report the short- and long-term results of the SOLIDARITY Finland on mortality and other patient-important outcomes in patients hospitalised for COVID-19. Between 08/2021 and 03/2023, we randomised 156 patients in 15 hospitals. In the imatinib group, 7.2% of patients had died at 30 days and 13.3% at 1 year and in the standard of care group 4.1% and 8.3% (adjusted HR at 30 days 1.09, 95% CI 0.23-5.07). In a meta-analysis of randomised trials of imatinib versus standard of care (n=732), allocation to imatinib was associated with a mortality risk ratio of 0.73 (95% CI 0.32-1.63). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in standard of care (RR 0.91, 95% CI 0.78-1.06). Of the 21 potential long COVID symptoms, patients often reported moderate or major bother from fatigue (24%), sleeping problems (19%) and memory difficulties (17%). We found no convincing difference between imatinib and standard of care groups in quality of life or symptom outcomes. The evidence raises serious doubts regarding the benefit of imatinib in reducing mortality, improving recovery, and preventing potential long COVID symptoms when given to patients hospitalised for COVID-19.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 96%
- Convalescent plasma for outpatients with early COVID-19 94%
- Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials 94%
Similar papers in this journal
- Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials 93%
- CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults 92%
- What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study 92%
Similar papers in this journal
- A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial 95%
- Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial 95%
- Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial 94%
Similar papers in this journal
- Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19 94%
- The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial 92%
- Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV) 91%
Similar papers in this journal
- A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19 93%
- Pre-existing autoimmunity is associated with increased severity of COVID-19: A retrospective cohort study using data from the National COVID Cohort Collaborative (N3C) 92%
- Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.